In
collaboration
with
InvestHK,
HKSTP
joined
forces
with
the
LKS
Faculty
of
Medicine
at
The
University
of
Hong
Kong
(HKU)
and
the
Faculty
of
Medicine
at
The
Chinese
University
of
Hong
Kong
(CUHK)
for
the
first
time
to
form
a
delegation
and
led
16
prominent
life
and
health
technology
companies
to
showcase
at
BIO
2025
held
in
Boston,
USA.
The
HKSTP
Pavilion
highlighted
the
groundbreaking
technologies
and
products
of
its
park
companies,
featuring
innovative
solutions
across
diverse
fields
such
as
novel
drug
development,
diagnostic
technologies,
and
medical
innovation.
Among
the
16
participating
companies,
they
were
the
members
of
HKSTP’s
incubation
programmes
including
Incu-Bio
and
ELITE
Programme,
cutting-edge
work
from
the
InnoHK
research
centers,
and
other
outstanding
biotech
companies.
On
the
first
day
of
the
exhibition,
the
delegation
successfully
attracted
attention
from
global
industry
leaders,
corporate
partners,
and
venture
capital
firms.
During
BIO
2025,
HKSTP
and
its
park
companies
made
significant
strides
in
fostering
cross-border
innovation
ecosystems
and
exploring
new
market
opportunities:
- Immuno Cure, partnering with HKUMed, the developer of the first-in-human novel therapeutic HIV vaccine ICVAX, announced its collaboration with PharmaJet to explore the application of a needle-free vaccination solution, accelerating the global commercialization pathway for ICVAX.
- HKSTP signed a partnership agreement with DLRC to provide legal advisory services in clinical trials and certification, promoting global ecosystem collaboration and growth.
Ahead of BIO 2025, the delegation participated in the “2025 Biomedical Pitch Competition”, co-organized by the Boston Capital Investment Club (BCIC) and HKSTP. The event connects global life and health innovators with investors and business partners. Three HKSTP companies—ARBELE, GenEditBio, and Cogsmart—excelled in the preliminary rounds, competing against over 100 global life sciences firms, with ARBELE, HKUMed’s affiliated spin-off company, winning the championship, underscoring Hong Kong’s research excellence. Over the past three years, this platform has helped startups secure over USD 100 million in funding and connect with hundreds of international investors and partners, driving further business growth.
HKSTP is committed to propelling Hong Kong’s life sciences sector onto the global stage, showcasing the city’s unique strengths to attract international enterprises and talent. The delegation also organized networking events and visits, enabling Hong Kong companies to engage with overseas investors, leading corporations, and renowned academic institutions, including visits to MIT Professor Robert Langer (Described as “Edison of Medicine”), Harvard Innovation Labs, Cambridge Innovation Center, and more. This initiative reinforces Hong Kong’s sustainable development in life sciences and its role as a global innovation leader.
Appendix: List of Park Companies Participating in BIO 2025:
- Allegrow Biotech Limited
- ARBELE Limited
- Beth Bioinformatics Co., Limited
- Centre for Translational Stem Cell Biology
- The Centre for Virology, Vaccinology, and Therapeutics
- DECODE CURE Limited
- GenEditBio Limited
- Great Bay Bio
- Hong Kong Universal Biologicals Company Limited
- Immuno Cure Holding (HK) Limited
- The Institute for Innovation, Translation and Policy Research (ITPR)
- LEE’S PHARMACEUTICAL (HK) LIMITED
- Serilink Biotechnology Company Limited
- Xiaomo Biotech Limited
- XUXIN (HongKong) Biotechnology Co., Limited
- Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited
Hashtag: #HKSTP
The issuer is solely responsible for the content of this announcement.
Support InfoStride News' Credible Journalism: Only credible journalism can guarantee a fair, accountable and transparent society, including democracy and government. It involves a lot of efforts and money. We need your support. Click here to Donate